Targeted therapy and immunotherapies are the novel pharmacologic treatment strategies for metastatic melanoma. BRAF and MEK inhibitors effectively block the hyperactivation of the MAPK pathway in BRAF mutant melanomas and also have several other effects on melanoma cells and on the immune response. The aim of this work is to discuss the rationale, evidence and perspectives of approaches combining target and immunotherapy against melanoma. Areas covered: We first review the effects of BRAF and MEK inhibitors on melanoma cells and on the different components of the immune system. Afterwards, we summarize the results of the preclinical and clinical studies that have combined targeted therapy and immunotherapy for the treatment of melanoma. Expert opinion: Clinical applications of immunotherapy strategies have recently changed the therapeutic mainstay for metastatic melanoma. Biologic and initial preclinical data support their integration with innovative molecular targeted therapies, opening enormous perspectives for researchers in the effort of finding a definitive cure. Main open challenges are the definition of reliable research models, assessment of effective schedules, safety issues and designing of personalized approaches.

Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives

SANLORENZO, Martina;QUAGLINO, Pietro;FIERRO, Maria Teresa;AGLIETTA, Massimo;SANGIOLO, Dario
Last
2015-01-01

Abstract

Targeted therapy and immunotherapies are the novel pharmacologic treatment strategies for metastatic melanoma. BRAF and MEK inhibitors effectively block the hyperactivation of the MAPK pathway in BRAF mutant melanomas and also have several other effects on melanoma cells and on the immune response. The aim of this work is to discuss the rationale, evidence and perspectives of approaches combining target and immunotherapy against melanoma. Areas covered: We first review the effects of BRAF and MEK inhibitors on melanoma cells and on the different components of the immune system. Afterwards, we summarize the results of the preclinical and clinical studies that have combined targeted therapy and immunotherapy for the treatment of melanoma. Expert opinion: Clinical applications of immunotherapy strategies have recently changed the therapeutic mainstay for metastatic melanoma. Biologic and initial preclinical data support their integration with innovative molecular targeted therapies, opening enormous perspectives for researchers in the effort of finding a definitive cure. Main open challenges are the definition of reliable research models, assessment of effective schedules, safety issues and designing of personalized approaches.
2015
15
10
1491
1500
http://www.tandfonline.com/doi/full/10.1517/14712598.2015.1069272
BRAF inhibitors; immunotherapy; melanoma; targeted therapy
Sanlorenzo, Martina; Vujic, Igor; Moy, Adrian; Quaglino, Pietro; Fierro, Maria Teresa; Gammaitoni, Loretta; Carnevale-Schianca, Fabrizio; Aglietta, Ma...espandi
File in questo prodotto:
File Dimensione Formato  
Sanlorenzo 2015 Sinergy immunotherapy melanoma 14712598.2015.1069272 OPENACCESS.pdf

Accesso aperto

Descrizione: Articolo principale post-print autore
Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 633.47 kB
Formato Adobe PDF
633.47 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1523691
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact